Reporting COVID-19 Vaccination Data for Long-Term Care Facilities
CDC’s COVID Data Tracker provides COVID-19 vaccination data in the United States. Please visit the About COVID-19 Vaccine Delivered and Administration Data to better understand the IT systems behind the COVID-19 Data Tracker.
As of April 23, 2021 the federal Pharmacy Partnership for LTC Program has ended. Data on the Federal Pharmacy Partnership for Long-Term Care (LTC) Program Tracker page reflects cumulative totals as of 4/23/21. Minor updates will be made as data are cleaned and finalized. For more information on the background of this program, please visit the Understanding the Pharmacy Partnership for Long-Term Care Program page. For more information on current strategies to continue vaccinating residents and staff in LTC facilities, please visit the Ensuring Access to COVID-19 Vaccine in Long-Term Care Facilities page.
The Federal Pharmacy Partnership for Long-Term Care Program
The Federal Pharmacy Partnership for Long-term Care (LTC) Program is a partnership between CDC and CVS, Walgreens, and Managed Health Care Associates, Inc., to offer on-site COVID-19 vaccination services for residents of nursing homes and assisted living facilities.
This program is being implemented in close coordination with jurisdictions (states, territories, and local entities), long-term care facilities, federal partners, including the Centers for Medicare and Medicaid Services, and professional organizations, including the American Health Care Association and Leading Age.
Jurisdictions had the opportunity to launch the program as early as December 21, 2020 for Pfizer-BioNTech vaccine or December 28,2020 for Moderna vaccine.
- The Program provides COVID-19 vaccine to staff and residents in skilled nursing facilities (Part A) and assisted living and other similar facilities (Part B).
- Launch dates for Part A and Part B varied across jurisdictions.
Staff and Resident Vaccinations
These were determined based on administration type information received by CDC from pharmacy partners. Not all vaccine doses could be categorized as being administered to LTC staff or residents. Overall numbers of doses administered, people receiving at least one dose, and people who are fully vaccinated include all vaccinations given through the program, including those for which staff/resident status was not reported.
Doses distributed information for the Federal Pharmacy Partnership for Long-Term Care (LTC) Program is no longer being reported because distribution data cannot be separated for the Federal Pharmacy Partnership for Long-term Care (LTC) Program the pharmacy retail transfer program, and doses distributed from state allocations directly to pharmacies.
Timing of Updates
Daily updates might be delayed due to delays in reported data. Additionally, data on doses of vaccine administered through the Federal Pharmacy Partnership for Long-term Care (LTC) Program include those received by CDC as of 6:00 am ET on the day of reporting. Pharmacy partners report to CDC on doses administered as part of the Federal Pharmacy Partnership for Long-term Care (LTC) Program within 72 hours of administration. Updates will occur the following day when reporting coincides with a federal holiday.
Total Doses Administered
Are cumulative counts of individual COVID-19 vaccine doses administered to residents and staff in long-term care facilities participating in the Federal Pharmacy Partnership for Long-term Care (LTC) Program as reported to CDC by pharmacy partners.
People Receiving At Least One Dose* (Formerly “Receiving 1 or More Doses”)
Represents the total number of people who have received at least one dose of any type of vaccine.
People Who Are Fully Vaccinated*
Represents the number of people who have also received a second dose of a two-dose vaccine or one dose of a single-shot vaccine.
- For reporting on CDC COVID Data Tracker, CDC counts people as being “fully vaccinated” if they received two doses on different days (regardless of time interval) of the two-dose mRNA series or received one dose of a single-dose vaccine.
- This definition differs from the current CDC Interim Clinical Considerations in two ways:
- According to the interim guidance, the second dose of Pfizer-BioNTech and Moderna vaccines should be administered as close to the recommended interval as possible, but not earlier than recommended (i.e., 3 weeks [Pfizer-BioNTech] or 1 month [Moderna]). However, second doses administered within a grace period of 4 days earlier than the recommended date for the second dose are still considered valid. If it is not feasible to adhere to the recommended interval and a delay in vaccination is unavoidable, the second dose of Pfizer-BioNTech and Moderna COVID-19 vaccines may be administered up to 6 weeks (42 days) after the first dose. Currently, only limited data are available on efficacy of mRNA COVID-19 vaccines administered beyond this window.
- To ensure adequate time for an immune response to occur, a person is considered fully vaccinated greater than or equal to 2 weeks after completion of a two-dose mRNA series or single dose of Janssen vaccine.
*The number of people receiving at least one dose of vaccine and the number of people who are fully vaccinated were determined based on information reported to CDC by pharmacy partners on dose number, vaccine manufacturer, administration date, recipient ID, and date of submission.
Due to a delay in data syncing on March 13, 2021, 4,575,496 new doses administered were initially reported, which included records that were reported after 6:00 AM ET (the regular cutoff time for daily reporting). The site has since been updated to reflect the totals reported as of March 13 at 6:00 AM ET. Totals for March 14, 2021 reflect the number of doses reported through the regular daily reporting period.
Users can download .CSV files of all data presented on CDC’s COVID Data Tracker. Additional vaccination data sets for COVID-19 and other diseases can be found at https://data.cdc.gov/browse?category=Vaccinations.